

# Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction

## An Analysis of the National Lung Screening Trial

*Wassim W. Labaki, MD; Meng Xia, PhD; Susan Murray, ScD; Charles R. Hatt, PhD; Abdullah Al-Abcha, MD; Michael C. Ferrera, MD; Catherine A. Meldrum, PhD, RN; Lauren A. Keith, PhD; Craig J. Galbán, PhD; Douglas A. Arenberg, MD; Jeffrey L. Curtis, MD; Fernando J. Martinez, MD; Ella A. Kazerooni, MD; and MeiLan K. Han, MD*

CHEST 2021; 159(5):1812-1820

*Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.*

**e-Table 1. Multivariable Cox Regression Model of Lung Cancer Mortality**

	Hazard Ratio (95% CI)	p-value
Age (per 1-yr increase)	1.08 (1.04-1.13)	<0.001
Body mass index <sup>#</sup>		
• Linear term	0.99 (0.94-1.04)	0.61
• Quadratic term	1.00 (1.00-1.00)	0.78
Smoking pack-years (per 1-unit increase)	1.01 (1.01-1.02)	<0.001
Time since smoking cessation (per 1-yr increase)	0.87 (0.82-0.93)	<0.001
Family history of lung cancer (yes vs. no)	1.57 (1.02-2.43)	0.042
%LAA (per 1% increase)*	1.02 (1.00-1.05)	0.045

<sup>#</sup> Body mass index is centered on the mean (28.0 kg/m<sup>2</sup>) to avoid collinearity between linear and quadratic terms

\* %LAA: % low attenuation area (defined as the percent of lung volume with voxels < -950 Hounsfield Units on computed tomography of the chest)

**e-Table 2. Multivariable Cox Regression Model of All-Cause Mortality**

	Hazard Ratio (95% CI)	p-value
Age (per 1-yr increase)	1.09 (1.07-1.11)	<0.001
Female (vs. male)	0.70 (0.57-0.87)	0.001
Race and ethnicity		
• Non-Hispanic White	1.00 [reference group]	
• Non-Hispanic Black	2.34 (1.67-3.29)	<0.001
• Hispanic or other	0.68 (0.37-1.25)	0.22
Body mass index <sup>#</sup>		
• Linear term	1.00 (0.98-1.02)	0.88
• Quadratic term	1.00 (1.00-1.00)	0.02
Smoking pack-years (per 1-unit increase)	1.01 (1.01-1.01)	<0.001
Time since smoking cessation (per 1-yr increase)	0.96 (0.94-0.98)	<0.001
Family history of lung cancer (yes vs. no)	1.17 (0.94-1.46)	0.16
%LAA (per 1% increase)*	1.01 (1.00-1.03)	0.042

<sup>#</sup> Body mass index is centered on the mean (28.0 kg/m<sup>2</sup>) to avoid collinearity between linear and quadratic terms

\* %LAA: % low attenuation area (defined as the percent of lung volume with voxels < -950 Hounsfield Units on computed tomography of the chest)

**e-Table 3. Airflow obstruction on spirometry by %LAA group (> 1% vs. ≤ 1%) in different age and sex subgroups**

<b>FEMALE &lt; 65 YEARS</b>				
	<b>FEV<sub>1</sub>/FVC &lt; 0.7</b>	<b>FEV<sub>1</sub>/FVC ≥ 0.7</b>	<b>Total</b>	
				Sensitivity 50.8% (95% CI 44.5%- 57.2%)
<b>%LAA &gt; 1%</b>	<b>120</b>	<b>124</b>	<b>244</b>	Specificity 81.9% (95% CI 79.0%-84.8%)
<b>% LAA ≤ 1%</b>	<b>116</b>	<b>561</b>	<b>677</b>	PPV 49.2% (95% CI 42.9%-55.5%)
<b>Total</b>	<b>236</b>	<b>685</b>	<b>921</b>	NPV 82.9% (95% CI 80.0%-85.7%)
<b>FEMALE ≥ 65 YEARS</b>				
	<b>FEV<sub>1</sub>/FVC &lt; 0.7</b>	<b>FEV<sub>1</sub>/FVC ≥ 0.7</b>	<b>Total</b>	
				Sensitivity 65.3% (95% CI 56.8%-73.8%)
<b>%LAA &gt; 1%</b>	<b>79</b>	<b>57</b>	<b>136</b>	Specificity 72.6% (95% CI 66.5%-78.7%)
<b>% LAA ≤ 1%</b>	<b>42</b>	<b>151</b>	<b>193</b>	PPV 58.1% (95% CI 49.8%-66.4%)
<b>Total</b>	<b>121</b>	<b>208</b>	<b>329</b>	NPV 78.2% (95% CI 72.4%-84.1%)
<b>MALE &lt; 65 YEARS</b>				
	<b>FEV<sub>1</sub>/FVC &lt; 0.7</b>	<b>FEV<sub>1</sub>/FVC ≥ 0.7</b>	<b>Total</b>	
				Sensitivity 61.6% (95% CI 56.4%-66.7%)
<b>%LAA &gt; 1%</b>	<b>210</b>	<b>183</b>	<b>393</b>	Specificity 72.5% (95% CI 69.1%-75.9%)
<b>% LAA ≤ 1%</b>	<b>131</b>	<b>483</b>	<b>614</b>	PPV 53.4% (95% CI 48.5%-58.4%)
<b>Total</b>	<b>341</b>	<b>666</b>	<b>1007</b>	NPV 78.7% (95% CI 75.4%-81.9%)
<b>MALE ≥ 65 YEARS</b>				
	<b>FEV<sub>1</sub>/FVC &lt; 0.7</b>	<b>FEV<sub>1</sub>/FVC ≥ 0.7</b>	<b>Total</b>	
				Sensitivity 74.2% (95% CI 56.4%-66.7%)
<b>%LAA &gt; 1%</b>	<b>144</b>	<b>85</b>	<b>229</b>	Specificity 65.9% (95% CI 60.0%-71.8%)
<b>% LAA ≤ 1%</b>	<b>50</b>	<b>164</b>	<b>214</b>	PPV 62.9% (95% CI 56.6%-69.1%)
<b>Total</b>	<b>194</b>	<b>249</b>	<b>443</b>	NPV 76.6% (95% CI 71.0%-82.3%)

%LAA: % low attenuation area (defined as the percent of lung volume with voxels < -950 Hounsfield Units on computed tomography of the chest); FEV<sub>1</sub>: forced expiratory volume in the first second; FVC: forced vital capacity; CI: confidence intervals; PPV: positive predictive value; NPV: negative predictive value.

*Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.*

**e-Table 4. Associations between each of %LAA and FEV<sub>1</sub>/FVC < 0.7 with lung cancer incidence, lung cancer mortality and all-cause mortality in multivariable Cox regression models**


Outcome	%LAA*	FEV <sub>1</sub> /FVC < 0.7 <sup>^</sup>
Lung cancer incidence	HR 1.01 (1.00-1.03) p=0.14	HR 1.17 (0.85-1.60) p=0.33
Lung cancer mortality	HR 1.01 (0.98-1.04) p=0.64	HR 1.77 (1.03-3.05) p=0.04
All-cause mortality	HR 1.00 (0.98-1.02) p=0.83	HR 1.25 (0.91-1.72) p=0.16

%LAA: % low attenuation area (defined as the percent of lung volume with voxels < -950 Hounsfield Units on computed tomography of the chest); FEV<sub>1</sub>: forced expiratory volume in the first second; FVC: forced vital capacity; HR: hazard ratio

\*Cells represent hazard ratios with 95% confidence intervals and associated p-values for 1% increase in %LAA after adjustment for covariates.

<sup>^</sup>Cells represent hazard ratios with 95% confidence intervals and associated p-values for FEV<sub>1</sub>/FVC < 0.7 (compared to FEV<sub>1</sub>/FVC ≥ 0.7) after adjustment for covariates.

**e-Figure 1. Consort Diagram**



e-Figure 2. Histograms of %LAA in participants with and without airflow obstruction

